biOasis Technologies Inc. (BTI) is pleased to announce that Dr. H. Christian Fibiger has been appointed to the Board of Directors of the Company. More...

biOasis Technologies Inc. (BTI) is pleased to announce that Mr. Hugh MacNaught has accepted the position of Executive Vice President with the Company. More...

biOasis Technologies Inc. (TSX.V: BTI) is pleased to announce that David Browning has agreed to advise the Company on its development programs for p97 diagnostic products. More...

biOasis Technologies Inc. (TSX.V:BTI) is pleased to announce that Mr. Hugh MacNaught has agreed to advise the Company on its Global Business Development programs, commencing with the p97 biomarker for Alzheimer’s disease... More...

biOasis Technologies Inc. (BTI.V) is delighted to acknowledge and recognize Dr. (Leigh) Anderson, one of its scientific advisors, for his recent award, the 2009 Distinguished Achievement award in Proteomic Science. More...

biOasis Technologies Inc. (BTI.V) is delighted to acknowledge and recognize Dr. (Leigh) Anderson, one of its scientific advisors, for his recent award, the 2009 Distinguished Achievement award in Proteomic Science. More...

biOasis Technologies Inc. (TSX.V: BTI) is pleased to announce the appointment of Dr. Avi Livnat to its Scientific Advisory Board. Dr. Livnat is the former CEO and Founder of Quintiles Israel Ltd., a wholly owned subsidiary of Quintiles Transnational Inc., the world’s largest Contract Research Organization.More...

biOasis Technologies Inc. (TSX.V: BTI) is pleased to announce that it has entered into a second Collaborative Research Agreement (“CRA”) with The University of British Columbia (“UBC”). More...

biOasis Technologies Inc. (TSX.V: BTI) Vancouver, BC – is pleased to announce that it has closed the private placement announced April 16, 2009. The Company has issued a total of 1,000,000 units (the “Units”) at a price of $0.50 per Unit for gross proceeds of $500,000. More...

biOasis Technologies Inc. (TSX.V: BTI) is pleased to provide an update on its technologies and corporate activities. On April 7th, 2009, the Company disclosed that all 6.5 million warrants, that were part of the private placement completed in March... More...

biOasis Technologies Inc. (TSX.V: BTI) is pleased to announce that it has entered into a Collaborative Research Agreement (“CRA”) with The University of British Columbia (“UBC”). More...

biOasis Technologies Inc. (BTI.V) is pleased to announce that it has entered into a private placement of up to 1,000,000 units at a purchase price of $0.50 per unit for gross proceeds of up to $500,000. More...

biOasis Technologies Inc. (BTI.V) is pleased to announce that all Warrants and Agent Warrants expiring March 31, 2009 were exercised as of March 31, 2009 resulting in cash proceeds to the Company of $1.7 million. More...

biOasis Technologies Inc. (BTI) is pleased to announce that Mr. Mark Godsy has joined the Company to assist in the overall strategy of the Company. Mr. Godsy is a very successful and experienced entrepreneur working in the area... More...

biOasis Technologies Inc. (the “Company”) (TSX.V: “BTI”) announces that it has appointed Mahesh Kamat as an associate and lead blogger for the Company. Before joining the biOasis team, Mahesh worked on the development... More...

biOasis Technologies Inc. (the “Company”), (TSX.V: BTI) is pleased to announce that it has engaged the Anderson Forchung Group LLC (“Anderson Forchung”) of Washington, DC to develop a new SISCAPA Assay to measure the levels of p97 in human blood samples. More...

biOasis Technologies Inc. (the “Company”) (TSX.V: BTI) announces that the “proof of concept” study documenting the companies innovative approach for the eradication of brain tumors and treating other diseases in the Central... More...

biOasis Technologies Inc. (the “Company”), (TSX.V: BTI) announces that it has been granted Patent # 2,230,372 by the Canadian Intellectual Property Office. “This is a significant and important patent... More...

biOasis Technologies Inc. (the “Company”), (TSX.V: BTI) is pleased to announce the appointment of Mr. John McKay as a member of the Company’s Advisory Board.“John has vast expertise in the Pharmaceutical and... More...

biOasis Technologies Inc. (the “Company”), (TSX.V: BTI) is pleased to announce the appointment of Dr. Leigh Anderson as a member of the Company’s Scientific Advisory Board. More...

On April 3, 2008 the Company began trading under its new name biOasis Technologies Inc. (formerly W.R. Partners Ltd.) and new TSX Venture Exchange (the “Exchange”) symbol “BTI”, having completed its acquisition... More...